

Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity

Ulrich Herrlinger¹ · David T. W. Jones^{2,3} · Martin Glas^{1,4} · Elke Hattingen⁵ ·
Dorothee Gramatzki⁶ · Moritz Stuplich¹ · Jörg Felsberg⁷ · Oliver Bähr¹⁵ ·
Gerrit H. Gielen⁸ · Matthias Simon⁹ · Dorothee Wiewrodt¹⁶ · Martin Schabet¹⁷ ·
Volker Hovestadt^{3,10} · David Capper^{3,11,12} · Joachim P. Steinbach¹⁵ ·
Andreas von Deimling^{3,11,12} · Peter Lichter^{3,10} · Stefan M. Pfister^{2,3,13} ·
Michael Weller⁶ · Guido Reifenberger^{7,14}

Published online: 7 January 2016
© Springer-Verlag Berlin Heidelberg 2016

Erratum to: Acta Neuropathol DOI 10.1007/s00401-015-1495-z

The original version of this article contained errors in the alignment of several entries in Tables 4 and 5. The corrected Tables 4 and 5 are given below. The original article has been updated accordingly.

The online version of the original article can be found under doi:[10.1007/s00401-015-1495-z](https://doi.org/10.1007/s00401-015-1495-z).

✉ Ulrich Herrlinger
ulrich.herrlinger@ukb.uni-bonn.de

- ¹ Division of Neurooncology, Department of Neurology, University Medical Center Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany
- ² Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany
- ³ German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany
- ⁴ Institute of Reconstructive Neurobiology, Life and Brain Center, University of Bonn, Bonn, Germany
- ⁵ Division of Neuroradiology, Department of Radiology, University of Bonn, Bonn, Germany
- ⁶ Department of Neurology, University of Zurich, Zurich, Switzerland
- ⁷ Department of Neuropathology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- ⁸ Department of Neuropathology, University of Bonn, Bonn, Germany
- ⁹ Department of Neurosurgery, University of Bonn, Bonn, Germany

- ¹⁰ Division of Molecular Genetics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany
- ¹¹ Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany
- ¹² Department of Neuropathology, University of Heidelberg, Heidelberg, Germany
- ¹³ Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany
- ¹⁴ German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Heidelberg, Partner Site Essen/Düsseldorf, Düsseldorf, Germany
- ¹⁵ Dr. Senckenberg Institute of Neurooncology, University of Frankfurt, Frankfurt, Germany
- ¹⁶ Department of Neurosurgery, University of Münster, Münster, Germany
- ¹⁷ Department of Neurology, Klinikum Ludwigsburg, Ludwigsburg, Germany

Table 4 Univariate and multivariate Cox regression analysis regarding overall survival and single genetic factors

	Median survival in months		Risk ratio (lower–upper 95 % CI)	<i>p</i>
	Condition 1	Condition 2		
Univariate analysis				
<i>MGMT</i> promoter status	Methylated >37.1	Unmethylated 8.9	0.09 (0.02–0.44)	0.004
IDH/CIMP status	Mutant/positive 36.3	Wildtype/negative 14.1	0.31 (0.08–1.23)	0.08
1p/19q status	Codeleted >16.5	Not codeleted 34.8	0.44 (0.05–3.6)	0.44
Chromosome 7 gain	Yes 8.98	No >36.3	6.32 (1.78–22.5)	0.004
<i>EGFR</i> amplification	Yes 7.9	No 36.3	10.1 (2.0–51.1)	0.005
9p21 deletion	Yes 37.1	No 34.6	1.15 (0.33–4.0)	0.82
Chromosome 10 deletion	Yes 12.2	No 36.3	2.6 (0.77–8.73)	0.12
<i>CDK4</i> amplification	Yes 36.2	No 34.6	0.52 (0.1–2.6)	0.42
<i>MDM2</i> or <i>MDM4</i> amplification	Yes 14.1	No 34.6	1.06 (0.28–4.1)	0.93
Multivariate analysis				
<i>MGMT</i> promoter status	Methylated	Unmethylated	0.16 (0.03–0.95)	0.04
IDH/CIMP status	Mutant/positive	Wildtype/negative	1.27 (0.14–11.6)	0.83
Chromosome 7 gain	Yes	No	4.2 (0.49–36.3)	0.19
<i>EGFR</i> amplification	Yes	No	3.0 (0.56–16.3)	0.20

Significant *p* values lower than 0.05 are in bold

Table 5 Univariate Cox regression analysis regarding the prognostic value MRI features for overall survival

MRI appearance	HR	95 % CI	<i>p</i>
Infratentorial involvement, yes vs. no	0.4	0.05–3.1	0.38
Involvement of 6 or more lobes, yes vs. no	1.08	0.33–3.5	0.9
Bilateral involvement, yes vs. no	0.67	0.08–5.4	0.71
Contrast enhancing lesions ^a , yes vs. no	1.39	0.37–5.3	0.63

HR hazard ratio, CI confidence interval

^a On the first MRI fulfilling the criteria of GC